ACAD FY 2023 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$726M+40.4% YoY

Gross Profit

$681M93.7% margin

Operating Income

-$73M-10.1% margin

Net Income

-$61M-8.4% margin

EPS (Diluted)

$-0.37

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

-$23M

Stock-Based Comp.

$66M

Balance Sheet

Total Assets

$749M

Total Liabilities

$317M

Stockholders' Equity

$432M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$726M	$517M	+40.4%
Gross Profit	$681M	$507M	+34.2%
Operating Income	-$73M	-$224M	+67.2%
Net Income	-$61M	-$216M	+71.6%